This is in accordance with previous work showing that when targeted therapy is effective in EGFR-mutated cancer cell lines, EGFR is downregulated [16], and further supports the effectiveness of the crizotinib and osimertinib combination in EGFR/MET-driven tumors. This evidence concerns the gene EGFR and cancer.